The losartan renal protection study : rationale, study design and baseline characteristics of RENAAL ( Reduction of endpoints in NIDDM with the Angiotensin II Antagonist Losartan)
Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.